TapewireFind a company

person · Reporting owner

Bjorkquist Jeanette M

Disclosed activity across 1 company

Tapewire entity
36779
SEC CIK
0001945064

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216PFO and PAOJune 17, 2026June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ASSEMBLY BIOSCIENCES, INC.

Report date June 17, 2026 · Filed June 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,560 Reported balance After 2026-06-17 transaction · row 1
1 source row

Row 1 · 2026-06-17 · Sale · Disposed 29 · Balance 14,560

F1: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 17, 2026 Filed Jun 18, 2026 20:05 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 29 $23.25 $674.25
Disclosure

SEC source: 0001193125-26-275804 · ownership.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,560

F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

Read SEC document
March 30, 2026 Filed Mar 31, 2026 20:25 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 16 $27.49 $439.84
Disclosure

SEC source: 0001193125-26-134669 · ownership.xml · nonDerivative · entry 3

Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,089

F4 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $27.84, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
March 30, 2026 Filed Mar 31, 2026 20:25 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 312 $26.65 $8,314.86
Disclosure

SEC source: 0001193125-26-134669 · ownership.xml · nonDerivative · entry 2

Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,105

F4 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.26, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
March 29, 2026 Filed Mar 31, 2026 20:25 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantCommon Stock 6,500 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-134669 · ownership.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,417

F1 · shares: Grant of restricted stock units ("RSUs"). The RSUs vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.

F2 · shares: RSUs represent 65% of the reporting person's annual equity grant. The remaining 35% of the RSUs granted are contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increases the number of shares of common stock authorized for issuance under the Plan.

F3 · balance_after: Reflects 300 fewer shares than were included in Column 5 on reporting person's prior Form 4 due to an administrative error.

Read SEC document
March 29, 2026 Filed Jun 5, 2026 20:25 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantCommon Stock 3,500 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-259661 · ownership.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,589

F1 · shares: Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.

Read SEC document
June 16, 2025 Filed Jun 17, 2025 20:05 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantStock Option (right to buy) · Derivative 600 $0.00 Strike: $17.24 $0.00
Disclosure

SEC source: 0000950170-25-087346 · ownership.xml · derivative · entry 2

Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600

Underlying: Common Stock · 600 shares

Expires 2035-06-16

F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, June 16, 2026; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on June 16, 2029.

Read SEC document
June 16, 2025 Filed Jun 17, 2025 20:05 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantCommon Stock 300 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-087346 · ownership.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,097

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: June 16, 2026; June 16, 2027; June 16, 2028; and June 16, 2029.

Read SEC document
March 31, 2025 Filed Apr 1, 2025 20:05 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 180 $9.85 $1,772.66
Disclosure

SEC source: 0000950170-25-048487 · ownership.xml · nonDerivative · entry 2

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,617

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.56 to $10.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
March 29, 2025 Filed Apr 1, 2025 20:05 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantStock Option (right to buy) · Derivative 1,900 $0.00 Strike: $10.62 $0.00
Disclosure

SEC source: 0000950170-25-048487 · ownership.xml · derivative · entry 3

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,900

Underlying: Common Stock · 1,900 shares

Expires 2035-03-29

F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2026; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2029.

Read SEC document
March 29, 2025 Filed Apr 1, 2025 20:05 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantCommon Stock 1,655 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-048487 · ownership.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,797

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2026; March 29, 2027; March 29, 2028; and March 29, 2029.

Read SEC document
May 23, 2024 Filed May 24, 2024 20:10 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 24 $14.93 $358.41
Disclosure

SEC source: 0000950170-24-064589 · ownership.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,142

F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 to $15.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
April 01, 2024 Filed Apr 2, 2024 20:20 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 114 $13.07 $1,490.20
Disclosure

SEC source: 0000950170-24-040180 · ownership.xml · nonDerivative · entry 2

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,166

F3 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.30, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
March 29, 2024 Filed Apr 2, 2024 20:20 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantStock Option (right to buy) · Derivative 1,550 $0.00 Strike: $13.30 $0.00
Disclosure

SEC source: 0000950170-24-040180 · ownership.xml · derivative · entry 3

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,550

Underlying: Common Stock · 1,550 shares

Expires 2034-03-29

F5 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2025; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2028.

Read SEC document
March 29, 2024 Filed Apr 2, 2024 20:20 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantCommon Stock 850 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-040180 · ownership.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,280

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2025; March 29, 2026; March 29, 2027; and March 29, 2028.

F2 · balance_after: Reflects equitable adjustment of the number of shares beneficially owned by the reporting person resulting from a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2023, which is exempt from reporting pursuant to Rule 16a-9.

Read SEC document
July 24, 2023 Filed Jul 25, 2023 20:30 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 844 $1.07 $900.38
Disclosure

SEC source: 0001209191-23-043309 · doc4.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,688

F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.05 to $1.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
May 23, 2023 Filed May 24, 2023 21:10 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 274 $1.04 $285.04
Disclosure

SEC source: 0001209191-23-031918 · doc4.xml · nonDerivative · entry 2

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,532

F3 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
May 22, 2023 Filed May 24, 2023 21:10 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantCommon Stock 1,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-031918 · doc4.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,806

F1 · shares: Represents shares of common stock issuable under a performance-based restricted stock unit award dated July 22, 2021. On May 22, 2023, the performance-based vesting conditions were achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: May 22, 2023 and May 22, 2024.

F2 · balance_after: Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on May 12, 2023.

Read SEC document
March 30, 2023 Filed Mar 31, 2023 20:40 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 SaleCommon Stock 774 $0.82 $637.16
Disclosure

SEC source: 0001209191-23-021882 · doc4.xml · nonDerivative · entry 2

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,806

F3 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7795 to $0.89, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Read SEC document
March 29, 2023 Filed Mar 31, 2023 20:40 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantStock Option (right to buy) · Derivative 12,500 $0.00 Strike: $0.89 $0.00
Disclosure

SEC source: 0001209191-23-021882 · doc4.xml · derivative · entry 4

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-03-29

F1 · derivative.exercise_date: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2024; March 29, 2025; March 29, 2026; and March 29, 2027.

Read SEC document
March 29, 2023 Filed Mar 31, 2023 20:40 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantCommon Stock 6,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-021882 · doc4.xml · nonDerivative · entry 1

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,580

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2024; March 29, 2025; March 29, 2026; and March 29, 2027.

F2 · balance_after: Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on November 14, 2022.

Read SEC document
February 16, 2023 Filed Mar 31, 2023 20:40 UTC ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 GrantStock Option (right to buy) · Derivative 2,000 $0.00 Strike: $1.53 $0.00
Disclosure

SEC source: 0001209191-23-021882 · doc4.xml · derivative · entry 3

Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires 2033-02-16

F5 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, February 16, 2024; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on February 16, 2027.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.